192661-47-5

Usage

Uses

Used in Pharmaceutical Industry:
3-Methylmorpholine hydrochloride is used as a catalyst and a reactant for the synthesis of pharmaceuticals, facilitating various chemical reactions and improving the production process.
Used in Agrochemical Industry:
3-Methylmorpholine hydrochloride is used as a catalyst and a reactant in the synthesis of agrochemicals, contributing to the development of effective products for agricultural applications.
Used in Polymer Manufacturing:
3-Methylmorpholine hydrochloride is used as a reactant in the manufacturing of polymers, playing a crucial role in the formation of specific polymer structures.
Used in Dye Production:
3-Methylmorpholine hydrochloride is used as a reactant in the production of dyes, enabling the synthesis of a wide range of colorants for various industries.
Used in Surfactant Production:
3-Methylmorpholine hydrochloride is used as a reactant in the manufacturing of surfactants, which are essential for creating products with desired properties in various applications.
It is important to handle 3-Methylmorpholine hydrochloride with caution and follow proper safety procedures due to its potential hazards.

Upstream product

• 570398-22-0 (R)-4-(4-methoxybenzyl)-5-methylmorpholin-3-one 
• 120800-86-4 (5R)-5-methyl-4-(phenylmethyl)-3-morpholinone 
• 74571-98-5 (3R)-3-methyl-4-(phenylmethyl)morpholine 
• 954133-47-2 (R)-4-(4-methoxybenzyl)-3-methylmorpholine 

Downstream Products

• 1445593-55-4 ((1R,2S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopropyl)((R)-3-methylmorpholino)methanone 
• 1445593-53-2 ((1S,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopropyl)((R)-3-methylmorpholino)methanone 
• 1445590-82-8 ((7R,8R)-8-(5-(4-bromophenyl)-1H-imidazol-2-yl)-1,4-dioxaspiro[4.4]nonan-7-yl)((R)-3-methylmorpholino)methanone 
• 1445590-34-0 ((1,2-trans)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclobutyl)((R)-3-methylmorpholino)methanone 
• 1350767-62-2 C₂₁H₂₆N₆O₂ 

Relevant academic research and scientific papers

Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease

We herein describe the results of further evolution of GSK-3β inhibitors for Alzheimer's disease from our promising compounds with in vivo tau phosphorylation inhibitory activity by oral administration. Introduction of a low alkyl group instead of the phenyl group at the 3-position of the morpholine moiety aiming to improve pharmacokinetic profiles resulted in potent low molecular weight GSK-3β inhibitors with good in vitro pharmacokinetic profiles, which also showed in vivo tau phosphorylation inhibitory activity by oral administration. Effect of the stereochemistry of the alkyl moiety is also discussed using docking models.

Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors

Phosphoinositide-dependent protein kinase-1(PDK1) is a master regulator of the AGC family of kinases and an integral component of the PI3K/AKT/mTOR pathway. As this pathway is among the most commonly deregulated across all cancers, a selective inhibitor of PDK1 might have utility as an anticancer agent. Herein we describe our lead optimization of compound 1 toward highly potent and selective PDK1 inhibitors via a structure-based design strategy. The most potent and selective inhibitors demonstrated submicromolar activity as measured by inhibition of phosphorylation of PDK1 substrates as well as antiproliferative activity against a subset of AML cell lines. In addition, reduction of phosphorylation of PDK1 substrates was demonstrated in vivo in mice bearing OCl-AML2 xenografts. These observations demonstrate the utility of these molecules as tools to further delineate the biology of PDK1 and the potential pharmacological uses of a PDK1 inhibitor.

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

CHEMICAL COMPOUNDS

The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof (I) wherein R2 represents a hydrogen or the like; R3 represents methyl group or the like; R20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the like; R6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH2, oxygen atom, NH, or the like; any one or more of R5 and R6, R5 and R4, R6 and R4, X and R5, X and R4, X and R6, and R6 and R6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).